中医药抗肝纤维化疗效评价的探索

我国在利用中成药治疗肝纤维化方面已走在国际前列。建议从抗肝纤维化的近期疗效、长期疗效和症状改善疗效3个方面开展评价,并介绍了笔者探索应用肝脏弹性测量值评价中成药抗纤维化的临床疗效,以5年生存率评价长期疗效,以及采用＂中医证候评定量表＂评价症状改善疗效的实践结果,显示出中成药扶正化瘀胶囊/片抗肝纤维化的临床疗效显著。建议配合血清学诊断模型,开展前瞻性的长期随访和对长期积累的大样本、大数据作分析,以完善抗肝纤维化疗效评价方法。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 33; no. 5; pp. 825 - 828
Main Author 徐列明
Format Journal Article
LanguageChinese
Published 上海中医药大学附属曙光医院,上海中医药大学肝病研究所,上海201203 2017
Subjects
中成药
治疗结果
肝硬化
治疗结果
中成药
treatment outcome
肝硬化
liver cirrhosis
Chinese patent drugs
Online AccessGet full text
ISSN1001-5256
DOI10.3969/j.issn.1001-5256.2017.05.006

Cover

More Information
Summary:我国在利用中成药治疗肝纤维化方面已走在国际前列。建议从抗肝纤维化的近期疗效、长期疗效和症状改善疗效3个方面开展评价,并介绍了笔者探索应用肝脏弹性测量值评价中成药抗纤维化的临床疗效,以5年生存率评价长期疗效,以及采用＂中医证候评定量表＂评价症状改善疗效的实践结果,显示出中成药扶正化瘀胶囊/片抗肝纤维化的临床疗效显著。建议配合血清学诊断模型,开展前瞻性的长期随访和对长期积累的大样本、大数据作分析,以完善抗肝纤维化疗效评价方法。
Bibliography:liver cirrhosis; Chinese patent drugs; treatment outcome
XU Lieming. （ Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ＆ Institute of ltepatology, Shanghai Uni- versity of Traditional Chinese Medicine, Shanghai 201203, China）
China has become one of the leading counties in the world to treat hepatic fibrosis with Chinese patent drugs. The therapeutic effect of traditional Chinese medicine （TCM） should be evaluated from the aspects of short -term therapeutic effect, long- term therapeutic effect, and effect of relief of symptoms. This article introduces the results of bur exploration of the application of liver stiffness measurement to evaluate therapeutic effect, five -year survival rate to assess long - term therapeutic effect, and a ＂TCM syndrome scale＂ to evaluate effect of relief of symptoms, suggesting that the Chinese patent drug Fuzheng Huayn capsules/tablets have a marked clinical effect in the treatment of hepatic fibrosis. It is recommended to use serological diagno
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2017.05.006